Dutch consortium investigates biomarker to identify early-stage melanoma at high-risk of recurrence

Source: PR Newswire, February 2021

Today, SkylineDx announced a research collaboration with an academic hospital and a Dutch cancer registry to investigate patients with early-stage melanoma (skin cancer) at high risk of disease-related fatality. Approximately 90% of all melanoma patients are diagnosed with an early-stage melanoma (American Joint Classification on Cancer [AJCC] stage I/II), without any lymph node metastasis or distant metastasis at time of diagnosis. However, 41% of melanoma-related deaths, are these early-stage patients that are anticipated to have a good prognosis at their diagnosis.